Two High-Risk Prostate Cancer Treatments Have Similar Benefits, Add-On Study Finds
News
Two treatment approaches — Zytiga (abiraterone acetate) plus prednisolone (AAP) or Taxotere (docetaxel) — provided patients with high-risk prostate cancer similar benefits when added to standard hormone deprivation therapy, according ... Read more